In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants

Journal of General Virology

Volumn 83, Issue 1, 2002, Pages 93-101

  Iglesias Ussel, M D ^a   Casado, C ^a   Yuste, E ^a   Olivares, I ^a   Lopez Galindez C ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EVOLUTION; FITNESS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOLECULAR CLONING; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS CULTURE; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0036135710     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-83-1-93     Document Type: Article

References (64)

1. Competition between species: Frequency dependence
2. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase
3. Rapid and simple method for purification of nucleic acids
4. Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug
5. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects
6. Fitness of RNA virus decreased by Muller's ratchet
7. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
8. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
9. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
10. + cell counts, and HIV-1 production by cells
11. Populations dynamics of HIV drug resistance
12. HIV inhibitors targeted at the reverse transcriptase
13. RNA virus quasispecies populations can suppress vastly superior mutant progeny
14. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays
15. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus
16. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: Vitro phenotypic and genotypic analyses
17. Sequence space and quasispecies distribution
18. Genetic lesions associated with Muller's ratchet in an RNA virus
19. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex
20. Vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine
21. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1
22. Human immunodeficiency virus fitness in vivo: Calculations based on single zidovudine resistance mutation at codon 215 of reverse transcriptase
23. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215
24. Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC
25. Clonal selection of human immunodeficiency virus (HIV): Serological differences in the envelope antigens of the cloned viruses and HIV prototypes (HTLV-III B, LAV, and ARV)
26. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility
27. Non-nucleoside reverse transcriptase inhibitors - Clinical aspects
28. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients
29. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses
30. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance
31. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
32. Human retroviruses and AIDS 1998: A compilation and analysis of nucleic acid and amino acid sequences
33. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
34. Site-specific mutagenesis of AIDS virus reverse transcriptase
35. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
36. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay
37. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture
38. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes
39. Resistencia a los fármacos antirretrovirales
40. Neutralization of HIV-1 infection of human peripheral blood mononuclear cells
41. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations
42. Clonal interference and the evolution of RNA viruses
43. 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro
44. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells
45. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
46. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure
47. The relation of recombination to mutational advance
48. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates
49. Pol gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy
50. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors
51. Phenotypic switch in a Spanish HIV type 1 isolate on serial passage on MT-4 cells
52. Complete sequence of an infectious molecular clone derived from a Spanish HIV type 1 isolate
53. Human-tumor-derived cell lines contain common and different transforming genes
54. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate
55. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture
56. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
57. Comparison of in vivo plasma and peripheral blood mononuclear cell HIV-1 quasispecies to short-term tissue culture isolates: An analysis of tat and C2-V3 env regions
58. Dilute passage promotes expression of genetic and phenotypic variants of human immunodeficiency virus type 1 in cell culture
59. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors
60. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1
61. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors
62. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase
63. The fastest genome evolution ever described: HIV variation in situ
64. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events